Variables

Values

Variants of AAV (n, %)

MPA

GPA

EGPA

Serotype of AAV (n, %)

MPO-ANCA positive

PR3-ANCA positive

Age (years)

Male gender (n, %)

General manifestations (n, %)

Skin involvement (n, %)

ENT involvement (n, %)

Cardiovascular involvement (n, %)

Abdominal involvement (n, %)

Nervous systemic involvement (n, %)

Pulmonary involvement (n, %)

Alveolar hemorrhage (n, %)

Interstitial lung disease (n, %)

Kidney involvement (n, %)

Proteinuria and /or hematuria (n, %)

SCR (μmol/L)

Hemoglobin (g/L)

Serum albumin (g/L)

Complement C3 (g/L) (0.8 - 1.52 g/L)

Complement C4 (g/L) (0.16 - 0.38 g/L)

BVAS

Immunosuppressive treatment (n, %)

Death (n, %)

Infection

Follow-up time (months)

258 (73.9)

74 (21.2)

17 (4.9)

316 (90.5)

33 (9.5)

63.6 ± 12.7

165 (47.3)

242 (69.3)

22 (6.3)

15 (4.3)

112 (32.1)

100 (28.7)

39 (11.2)

164 (47.0)

48 (13.8)

102 (29.2)

287 (82.2)

258 (73.9)

223 (77, 575.5)

91 (75.5, 109.0)

30 (26, 35)

0.79 (0.66, 0.93)

0.22 (0.17, 0.27)

15 (10, 18)

207 (59.3)

138 (42.7)

73 (52.9)

23.0 (7.5, 45.7)